Evidence map›Paper›PMID 31028604›Full record

ArticleMolecular biotechnology2019

Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells.

Bilge Debelec-Butuner, Mustafa Kotmakci, Ezgi Oner, Gulseren Ozduman, Ayse Gulten Kantarci

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Honokiol inhibits the growth of SKBR3 cells.Translational cancer research · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bilge Debelec-ButunerDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey. bilge.debelec@ege.edu.tr.
Mustafa KotmakciDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey.
Ezgi OnerDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey.
Gulseren OzdumanDepartment of Biotechnology, Graduate School of Science, Ege University, 35100, Bornova, Izmir, Turkey.
Ayse Gulten KantarciDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey.
Ege University · TR

Funding

Ege University 16ECZ031
6 · The paper itself

Abstract

Escape from apoptosis, one of the characteristic features of cancer cells, is a case that reduces the therapeutic efficacy of apoptosis-inducing molecules used in the cancer treatment. Stabilization of the P53 protein, which is responsible for the regulation of apoptosis mechanism in the cell, is therefore an important therapeutic goal. Nutlin3a inhibits the degradation of the P53 protein, triggers P53-mediated apoptosis in cancer cells and enhances the effectiveness of chemotherapeutics. However, its low aqueous solubility is the major disadvantage when it comes to in vivo administration. In order to facilitate an aqueous formulation of Nutlin3a and to enhance its apoptotic activity on cancer cells, Nutlin3a was encapsulated in solid lipid nanoparticles (SLNs) prepared by Ouzo method. Physicochemical characterization was performed and activity of apoptosis induction on wild-type P53 expressing LNCaP prostate cancer cell line was evaluated. Nutlin3a-loaded cationic solid lipid nanoparticles were found to stabilize functional P53 at protein level. In addition, induction rate of apoptosis by nanoparticles was higher than Nutlin3a solution in DMSO, proving this nanoparticle formulation is a promising candidate for increasing the efficiency of Nutlin3a for P53(+) cancer cases. Thus, it is anticipated that the results will contribute to evaluate the use of lipid-based nanocarriers to enhance the therapeutic potential of small molecules that are important in cancer cure.

Indexed as

Drug Delivery SystemsNanoparticlesAntineoplastic AgentsApoptosisCell Line, TumorHumansImidazolesMalePiperazinesProstatic NeoplasmsTumor Suppressor Protein p53Antineoplastic AgentsImidazolesnutlin 3PiperazinesTP53 protein, humanTumor Suppressor Protein p53NanocarrierNutlin3aP53Prostate cancerSolid lipid nanoparticle

Identifiers

PMID31028604
OpenAlexW2941882739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.